{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T12:02:40Z","timestamp":1790337760643,"version":"4.1.0"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacological and Toxicological Methods"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.vascn.2026.108561","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T23:32:43Z","timestamp":1784244763000},"page":"108561","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Redefining cardiovascular safety: A dual-pathway, mechanistic in silico screen for the detection of trafficking-mediated and \u201chidden\u201d cardiotoxicity"],"prefix":"10.1016","volume":"140","author":[{"given":"Mustafa","family":"Al Yagoub","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vascn.2026.108561_bb0005","doi-asserted-by":"crossref","DOI":"10.1111\/cts.70451","article-title":"Reassessing the conduct of patch clamp cardiac ion channel assays to improve nonclinical data translation to clinical ECG changes and proarrhythmia risk","author":"Alvarez Baron","year":"2025","journal-title":"Clinical and Translational Science"},{"key":"10.1016\/j.vascn.2026.108561_bb0010","first-page":"108","article-title":"Endoxifen, the active metabolite of tamoxifen, inhibits cloned hERG potassium channels","volume":"754","author":"Chae","year":"2015","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.vascn.2026.108561_bb0015","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.vascn.2016.06.002","article-title":"The comprehensive in vitro proarrhythmia assay (CiPA) initiative \u2014 Update on progress","volume":"81","author":"Colatsky","year":"2016","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2026.108561_bb0020","doi-asserted-by":"crossref","DOI":"10.1186\/1758-2652-11-S1-P101","article-title":"Evaluation of the impact of lopinavir\/ritonavir (LPV\/r) and ritonavir (RTV) on PR interval: Results from a thorough QT study","volume":"11","author":"Da Silva","year":"2008","journal-title":"Journal of the International AIDS Society"},{"key":"10.1016\/j.vascn.2026.108561_bb0025","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1124\/mol.66.1.33","article-title":"Mechanisms of arsenic-induced prolongation of cardiac repolarization","volume":"66","author":"Ficker","year":"2004","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.vascn.2026.108561_bb0030","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1124\/mol.110.069419","article-title":"Involvement of caveolin in probucol-induced reduction in hERG plasma-membrane expression","volume":"79","author":"Guo","year":"2011","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.vascn.2026.108561_bb0035","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1124\/jpet.107.120931","article-title":"Probucol blocks hERG channel trafficking and reduces IKr in cardiac myocytes","volume":"321","author":"Guo","year":"2007","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.vascn.2026.108561_bb0040","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3390\/biomedicines10020244","article-title":"Acetylcholine reduces IKr and prolongs action potentials in human ventricular cardiomyocytes","volume":"10","author":"Koncz","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.vascn.2026.108561_bb0045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0221763","article-title":"Comparison of in vitro and computational experiments on the relation of inter-beat interval and duration of repolarization in a specific type of human induced pluripotent stem cell-derived cardiomyocytes","volume":"14","author":"K\u00fcgler","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.vascn.2026.108561_bb0050","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1124\/jpet.104.073692","article-title":"Pentamidine-induced long QT syndrome and block of hERG trafficking","volume":"312","author":"Kuryshev","year":"2005","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.vascn.2026.108561_bb0055","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1093\/cvr\/cvab375","article-title":"Electrophysiological heterogeneity in large populations of rabbit ventricular cardiomyocytes","volume":"118","author":"Lachaud","year":"2022","journal-title":"Cardiovascular Research"},{"key":"10.1016\/j.vascn.2026.108561_bb0060","article-title":"Improving the in silico assessment of proarrhythmia risk by combining hERG channel\u2013drug binding kinetics and multichannel pharmacology","volume":"10","author":"Li","year":"2017","journal-title":"Circulation: Arrhythmia and Electrophysiology"},{"key":"10.1016\/j.vascn.2026.108561_bb0065","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1002\/cpt.1184","article-title":"Assessment of an in silico mechanistic model for proarrhythmia risk prediction under the CiPA initiative","volume":"105","author":"Li","year":"2019","journal-title":"Clinical Pharmacology & Therapeutics"},{"key":"10.1016\/j.vascn.2026.108561_bb0070","series-title":"In silico methods for the prediction of drug-induced cardiotoxicity","author":"Mamoshina","year":"2020"},{"key":"10.1016\/j.vascn.2026.108561_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.aca.2025.343819","article-title":"Determination of lopinavir and ritonavir in herg solution to support in vitro herg block potency assessment using LC-MS\/MS: The challenge of poor drug solubility","author":"Mistry","year":"2025","journal-title":"Analytica Chimica Acta"},{"key":"10.1016\/j.vascn.2026.108561_bb0080","article-title":"Simulation of the undiseased human cardiac ventricular action potential: Model formulation and experimental validation","volume":"7","author":"O\u2019Hara","year":"2011","journal-title":"PLoS Computational Biology"},{"key":"10.1016\/j.vascn.2026.108561_bb0085","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/QAD.0b013e328341dcc0","article-title":"Boosted protease inhibitors and the electrocardiographic measures of QT and PR durations","volume":"25","author":"Soliman","year":"2011","journal-title":"AIDS"},{"key":"10.1016\/j.vascn.2026.108561_bb0090","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/cpt.1303","article-title":"Assessment of multi-ion channel block in a phase I randomized study design: Results of the CiPA phase I ECG biomarker validation study","volume":"105","author":"Vicente","year":"2019","journal-title":"Clinical Pharmacology & Therapeutics"}],"container-title":["Journal of Pharmacological and Toxicological Methods"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056871926001541?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056871926001541?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T11:22:48Z","timestamp":1790335368000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056871926001541"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":18,"alternative-id":["S1056871926001541"],"URL":"https:\/\/doi.org\/10.1016\/j.vascn.2026.108561","relation":{},"ISSN":["1056-8719"],"issn-type":[{"value":"1056-8719","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Redefining cardiovascular safety: A dual-pathway, mechanistic in silico screen for the detection of trafficking-mediated and \u201chidden\u201d cardiotoxicity","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmacological and Toxicological Methods","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vascn.2026.108561","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108561"}}